Research Roundup


Debbie Rigby wraps up the latest research news relevant to pharmacists…

Systematic review of red yeast rice compared with simvastatin in dyslipidaemia

Red yeast rice is believed to be a useful alternative in the management of dyslipidaemia. A systematic review of 10 randomized controlled trials involving 905 Chinese subjects with dyslipidaemia showed that red yeast rice and simvastatin produce similar lipid-lowering effects.

Journal of Clinical Pharmacy and Therapeutics 2016;41(2):170-9.

 

Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer

The U.S. Preventive Services Task Force has released an update on aspirin use to prevent cardiovascular disease (CVD) events and colorectal cancer. Low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.

Ann Intern Med. Published online 12 April 2016

Medscape summary

 

Bleeding Risks With Aspirin Use for Primary Prevention in Adults

In CVD primary prevention studies, low-dose aspirin use increased major gastrointestinal (GI) bleeding risk by 58% and haemorrhagic stroke risk by 27%. The authors conclude that use of aspirin in requires an individualized assessment of aspirin’s effects on bleeding risks and expected benefits because absolute bleeding risk may vary considerably by patient.

Ann Intern Med. Published online 12 April 2016

 

Simeprevir and Sofosbuvir for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection

The combination of simeprevir (SMV) and sofosbuvir (SOF) was found to be well-tolerated with high sustained virologic response (SVR) rates in patients with genotype 1 chronic hepatitis C in clinical trials. This retrospective study of ‘real-world’ data confirms high cure rates (SVR12) across different patient populations.

Am J Gastroenterol. 2016;111(2):250-260. 

 

 

 

 

 

 

 

Previous Panadol Osteo decision could shift patients to opioids
Next Follow UK with general practice pharmacists: PSA

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.